ArticleScientific reports2025
Lactate-to-albumin ratio as an independent predictor of 28-day ICU mortality in patients with hypertension: a retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between lactate-to-albumin ratio and 28-day mortality in critically ill patients with HFpEF: a retrospectively cohort study.Scientific reports · 2026Article
- Preoperative RDW-Based composite score for predicting mortality after hip fracture surgery.BMC musculoskeletal disorders · 2026Article
- Early Peri-Admission Lactate-to-Albumin (LAR), C-Reactive Protein-to-Albumin (CAR), and Procalcitonin-to-Albumin (PAR) Ratios and ICU Mortality in a Tertiary Cardiac ICU.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to explore the association between the lactate-to-albumin ratio (LAR) and the risk of mortality in critically ill patients with hypertension. This is a retrospective cohort study utilizing data from the Medical Information Mart for Intensive Care IV (MIMIC-IV, v3.1) database. Participants were categorized into tertiles based on LAR levels (low: <0.46, intermediate: 0.46-0.81, high: >0.81). The primary outcome was 28-day mortality. Kaplan-Meier curves were used to compare survival probabilities among patients in different LAR tertiles. Multivariable COX proportional hazards regression analysis and restricted cubic spline (RCS) regression were employed to assess the association between LAR levels and mortality in hypertensive patients. Additionally, subgroup and mediation analyses were conducted. A total of 4,504 patients were included in this study. Kaplan-Meier survival curves revealed that hypertensive patients in the highest LAR tertile had the highest mortality rate (log-rank test, P < 0.001). Multivariable COX regression analysis demonstrated that higher LAR levels were independently associated with an increased risk of 28-day mortality (HR: 1.240, 95% CI: 1.138-1.351, P < 0.001). Compared to the lowest LAR tertile, patients in the highest LAR tertile had a significantly increased 28-day mortality risk (HR = 1.229, 95% CI: 1.035-1.459, P = 0.019). In the fully adjusted model (Model 5), the highest LAR tertile was independently associated with a 22.9% increased mortality risk (HR = 1.229, 95% CI: 1.035-1.459, P = 0.019) compared to the lowest tertile. Restricted cubic spline (RCS) regression indicated a non-linear relationship between LAR levels and mortality risk in the unadjusted model (non-linear P-value = 0.026). Subgroup analysis further identified interactions between BMI, antihypertensive therapy, and mortality in hypertensive patients. Finally, mediation analysis suggested that SOFA and SAPS II scores partially mediated the association between LAR and ICU survival time. LAR demonstrates utility as a prognostic marker for 28-day mortality in critically ill hypertensive patients, particularly in those with obesity or untreated hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.